$26.99
1.81% today
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US45783C1018
Symbol
TIL

Instil Bio Inc Stock price

$26.99
-1.45 5.10% 1M
+6.77 33.48% 6M
+7.90 41.38% YTD
+14.49 115.92% 1Y
-77.81 74.25% 3Y
-373.01 93.25% 5Y
-373.01 93.25% 10Y
-373.01 93.25% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.48 1.81%
ISIN
US45783C1018
Symbol
TIL
Industry

Key metrics

Basic
Market capitalization
$179.0m
Enterprise Value
$159.5m
Net debt
positive
Cash
$103.7m
Shares outstanding
6.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
64.3%
Return on Equity
-43.7%
ROCE
-22.0%
ROIC
-
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-47.6m | -
EBIT
$-50.7m | $-84.1m
Net Income
$-78.1m | $-71.6m
Free Cash Flow
$-45.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
31.1% | -
EBIT
30.5% | -47.6%
Net Income
36.5% | 3.3%
Free Cash Flow
37.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-12.0
FCF per Share
$-7.0
Short interest
27.2%
Employees
14
Rev per Employee
$0.0
Show more

Is Instil Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Instil Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Instil Bio Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Instil Bio Inc forecast:

Buy
75%
Hold
25%

Financial data from Instil Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
11% 11%
-
- Research and Development Expense 9.95 9.95
62% 62%
-
-48 -48
31% 31%
-
- Depreciation and Amortization 3.12 3.12
21% 21%
-
EBIT (Operating Income) EBIT -51 -51
31% 31%
-
Net Profit -78 -78
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Instil Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Instil Bio Inc Stock News

Neutral
GlobeNewsWire
9 days ago
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025
Neutral
GlobeNewsWire
22 days ago
Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting toxicities observed in patients with front-line NSCLC ImmuneOnco expects to present updated safety and efficacy data at a future medical conference DALLAS and SHANGHAI, July 31, 2025 (GLOBE NEWSWI...
Neutral
GlobeNewsWire
about 2 months ago
US phase 1 trial of ‘2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies...
More Instil Bio Inc News

Company Profile

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Head office United States
CEO Bronson Crouch
Employees 14
Founded 2018
Website instilbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today